Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Proxy solicitation initiated by PVG Asset Management and Patrick S. Adams seeks to replace the entire Board with six new independent directors at the 2026 Annual Meeting.

• The campaign follows significant leadership changes, management departures, and perceived failures in investor relations and regulatory compliance.

• PVG criticizes the current Board for value destruction, poor oversight, and lack of relevant industry expertise, urging shareholders to vote for their nominees using the GOLD proxy card.

Voting matters and shareholder proposals

• Shareholders are asked to elect six PVG nominees to the Board, replacing up to six incumbent directors, including a recent appointee.

• Voting will be conducted via a universal proxy card, allowing selection of any combination of nominees up to six.

• PVG intends to solicit support from holders representing at least 67% of voting power.

Board of directors and corporate governance

• PVG's nominees include professionals with backgrounds in asset management, equity research, healthcare portfolio management, and biotech advisory.

• The current Board is criticized for lack of biotech and clinical expertise, with specific concerns about the Chair and committee heads.

• PVG claims the Board resisted shareholder-backed nominations and failed to communicate transparently about leadership transitions.